Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF): 2012-2024

Historic Depreciation & Amortization (CF) for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $28.2 million.

  • Amphastar Pharmaceuticals' Depreciation & Amortization (CF) fell 19.74% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year decrease of 20.51%. This contributed to the annual value of $28.2 million for FY2024, which is 9.76% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $28.2 million for FY2024, which was up 9.76% from $25.7 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Depreciation & Amortization (CF) peaked at $28.2 million during FY2024, and registered a low of $9.0 million during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $22.2 million, with a median of $25.7 million in 2023.
  • Data for Amphastar Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY spiked of 104.31% (in 2023) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $9.0 million in 2020, then grew by 13.23% to $10.2 million in 2021, then rose by 23.20% to $12.6 million in 2022, then surged by 104.31% to $25.7 million in 2023, then increased by 9.76% to $28.2 million in 2024.